Ronnie Shapira-Frommer
Overview
Explore the profile of Ronnie Shapira-Frommer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
10432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nethanel A, Kyprianou C, Barzilai A, Shapira-Frommer R, Shoham Y, Kornhaber R, et al.
Life (Basel)
. 2023 Sep;
13(9).
PMID: 37763207
An accurate and comprehensive histopathology report is essential for cutaneous melanoma management, providing critical information for accurate staging and risk estimation and determining the optimal surgical approach. In many institutions,...
12.
Bar-Hai N, Ben-Betzalel G, Stoff R, Grynberg S, Schachter J, Shapira-Frommer R, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37297003
Background: Successful treatment with Immune Checkpoint Inhibitors (ICI) requires the balanced activation of the immune system. Over-activation may result in immune-related adverse events (irAEs), which often require steroidal treatment. This...
13.
Stoff R, Asher N, Laks S, Steinberg Y, Schachter J, Shapira-Frommer R, et al.
Front Oncol
. 2023 Jun;
13:1180988.
PMID: 37274272
Introduction: Immunotherapy has revolutionized the prognosis of patients with metastatic melanoma. To date, the most active regimen is the combination of ipilimumab + nivolumab (ipi-nivo) achieving a response rate of...
14.
Lorusso D, Colombo N, Casado Herraez A, Santin A, Colomba E, Miller D, et al.
Eur J Cancer
. 2023 Apr;
186:172-184.
PMID: 37086595
Purpose: Lenvatinib and pembrolizumab (LEN+PEMBRO) demonstrated clinically meaningful and statistically significant improvements in efficacy versus treatment of physician's choice (TPC) in patients with advanced endometrial cancer (aEC) in the phase...
15.
Markovits E, Harush O, Baruch E, Shulman E, Debby A, Itzhaki O, et al.
Cancer Immunol Res
. 2023 Apr;
11(7):909-924.
PMID: 37074069
Immunotherapy has revolutionized the treatment of advanced melanoma. Because the pathways mediating resistance to immunotherapy are largely unknown, we conducted transcriptome profiling of preimmunotherapy tumor biopsies from patients with melanoma...
16.
Peleg Hasson S, Felder S, Helpman L, Taylor A, Shalamov M, Abuakar S, et al.
Int J Gynecol Cancer
. 2023 Mar;
33(5):683-691.
PMID: 36963801
Objective: The use of chemoradiation in patients with stage IVB cancer of the cervix was evaluated to determine if definitive treatment offers benefit. Methods: A database of 546 patients with...
17.
Monk B, Tewari K, Dubot C, Caceres M, Hasegawa K, Shapira-Frommer R, et al.
Lancet Oncol
. 2023 Mar;
24(4):392-402.
PMID: 36878237
Background: In the KEYNOTE-826 study, the addition of the anti-PD-1 monoclonal antibody pembrolizumab to chemotherapy with or without bevacizumab improved overall survival and progression-free survival (primary endpoints) versus placebo plus...
18.
Colomban O, Swisher E, Kristeleit R, McNeish I, Shapira-Frommer R, Goble S, et al.
EBioMedicine
. 2023 Feb;
89:104477.
PMID: 36801617
Background: PARP inhibitors (PARPi) have revolutionized the management of advanced ovarian carcinoma, and were investigated as forefront treatment in recurrent disease. The objective was to explore if mathematical modeling of...
19.
Kristeleit R, Drew Y, Oza A, Domchek S, Banerjee S, Glasspool R, et al.
Br J Cancer
. 2022 Dec;
128(2):255-265.
PMID: 36482193
Background: Study 10, a four-part Phase 1/2 study, evaluated oral rucaparib monotherapy in patients with advanced solid tumours. Here we report the final efficacy and safety results in heavily pretreated...
20.
Stoff R, Grynberg S, Asher N, Laks S, Steinberg Y, Schachter J, et al.
Front Oncol
. 2022 Nov;
12:1020058.
PMID: 36419899
Introduction: Immunotherapy has revolutionized metastatic Melanoma therapy. The most active regimen is combination therapy of Ipilimumab-Nivolumab (Ipi-Nivo) with response rates (RR) of ~60% and median overall survival (OS) of ~6...